105 related articles for article (PubMed ID: 17418977)
1. Pretreatment total testosterone levels in patients with prostate cancer in the past two decades in Japan.
Sekine Y; Ito K; Yamamoto T; Nakazato H; Shibata Y; Hatori M; Suzuki K
Cancer Detect Prev; 2007; 31(2):149-53. PubMed ID: 17418977
[TBL] [Abstract][Full Text] [Related]
2. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening.
Yano M; Imamoto T; Suzuki H; Fukasawa S; Kojima S; Komiya A; Naya Y; Ichikawa T
Eur Urol; 2007 Feb; 51(2):375-80. PubMed ID: 17005316
[TBL] [Abstract][Full Text] [Related]
3. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer.
Shimbo M; Suzuki H; Kamiya N; Imamoto T; Komiya A; Ueda T; Watanabe M; Shiraishi T; Ichikawa T
Eur Urol; 2005 Apr; 47(4):557-63. PubMed ID: 15774258
[TBL] [Abstract][Full Text] [Related]
4. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy.
Taira AV; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1143-9. PubMed ID: 19117691
[TBL] [Abstract][Full Text] [Related]
6. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
[TBL] [Abstract][Full Text] [Related]
7. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
[TBL] [Abstract][Full Text] [Related]
8. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer.
Yasuda K; Nagakawa O; Akashi T; Fujiuchi Y; Koizumi K; Komiya A; Saiki I; Fuse H
Prostate; 2009 Mar; 69(4):346-51. PubMed ID: 19021204
[TBL] [Abstract][Full Text] [Related]
9. Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels.
Ide H; Yasuda M; Nishio K; Saito K; Isotani S; Kamiyama Y; Muto S; Horie S
Anticancer Res; 2008; 28(4C):2487-92. PubMed ID: 18751439
[TBL] [Abstract][Full Text] [Related]
10. Variations in blood ghrelin levels in prostate cancer patients submitted to hormone suppressive treatment.
Bertaccini A; Pernetti R; Marchiori D; Pagotto U; Palladoro F; Palmieri F; Vitullo G; Guidi M; Martorana G
Anticancer Res; 2009 Apr; 29(4):1345-8. PubMed ID: 19414385
[TBL] [Abstract][Full Text] [Related]
11. Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients?
Imamoto T; Suzuki H; Yano M; Kawamura K; Kamiya N; Araki K; Komiya A; Naya Y; Shiraishi T; Ichikawa T
Prostate Cancer Prostatic Dis; 2009; 12(1):78-82. PubMed ID: 18521100
[TBL] [Abstract][Full Text] [Related]
12. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy.
Lane BR; Stephenson AJ; Magi-Galluzzi C; Lakin MM; Klein EA
Urology; 2008 Dec; 72(6):1240-5. PubMed ID: 18692874
[TBL] [Abstract][Full Text] [Related]
13. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
15. Absence of relationship between steroid hormone levels and prostate cancer tumor grade.
Sher DJ; Mantzoros C; Jacobus S; Regan MM; Lee GS; Oh WK
Urology; 2009 Feb; 73(2):356-61; discussion 361-2. PubMed ID: 19036418
[TBL] [Abstract][Full Text] [Related]
16. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer.
Palma D; Pickles T; Tyldesley S;
BJU Int; 2007 Aug; 100(2):315-9. PubMed ID: 17617138
[TBL] [Abstract][Full Text] [Related]
17. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
Bong GW; Clarke HS; Hancock WC; Keane TE
Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
[TBL] [Abstract][Full Text] [Related]
18. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
Hong SK; Han BK; Jeong JS; Jeong SJ; Moon KH; Byun SS; Lee SE
Asian J Androl; 2008 Mar; 10(2):207-13. PubMed ID: 18097534
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment hormone levels in prostatic cancer.
Haapiainen R; Rannikko S; Alfthan O; Adlercreutz H
Scand J Urol Nephrol Suppl; 1988; 110():137-43. PubMed ID: 3187401
[TBL] [Abstract][Full Text] [Related]
20. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
